
Amiodarone and simvastatin: A risky combination
FDA still receiving many adverse incidents about the concurrent administration of the two products.
Although a revision in simvastatin's labeling in 2002 warned that patients taking both the cholesterol-lowering drug and amiodarone are at increased risk of coming down with rhabdomyolysis, the Food and Drug Administration reports that it is still receiving all too many adverse incidents about the concurrent administration of these two products. The agency warned that the risk of rhabdomyolysis increases when simvastatin is given at doses greater than 20 mg a day along with
To see more Daily News articles,
To go to the Drug Topics homepage,
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.





































































































































